Prevail provided an update today on the advancement of its gene therapy program for patients with Parkinson’s disease with GBA1 mutations.
Prevail Therapeutics (NASDAQ:PRVL) provided an update today on the clinical advancement of its gene therapy program PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA).
As quoted in the press release:
Enrollment in the PR001 Phase 1/2 PROPEL clinical trial is progressing, patient dosing continues, and the Company is on track to report interim data on a subset of patients in the second half of 2020.
The Company will present on its clinical progress at the Cowen & Co. Annual Healthcare Conference in Boston today.
“We believe the PROPEL trial makes PR001 the first potentially disease-modifying gene therapy for PD-GBA patients to enter clinical trials. Its ongoing progress brings us a step closer to new treatment options for patients living with PD-GBA,” said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail. “We are excited about the potential of PR001 to slow or stop disease progression for PD-GBA patients.”